CLAIMS:

1. Use of mometasone furoate and olopatadine hydrochloride in the manufacture of a fixed-dose pharmaceutical composition for treating one or more symptoms associated with allergic rhinitis in a pediatric human subject in need thereof, wherein

(i) the composition is to be nasally administered as one spray per nostril of the pediatric human subject twice daily,

(ii) the composition comprises a hydrocolloid at a concentration of 0.1 % w/w to 3 % w/w,

(iii) each spray comprises about 25 mcg of mometasone furoate and about 665 mcg olopatadine hydrochloride,

(iv) the fixed-dose pharmaceutical composition is a suspension wherein the mometasone furoate is in particulate form with a mean particle size of from 1 to 20 μm, and the olopatadine hydrochloride is in solution form, and

(v) the pediatric human subject is aged 6 to under 12 years.

2. The use of claim 1, wherein the one or more symptoms are selected from nasal congestion, rhinorrhea, itching and sneezing.

3. The use of claim 1, wherein the allergic rhinitis is seasonal allergic rhinitis.

4. The use of claim 1, wherein the allergic rhinitis is perennial allergic rhinitis.

5. The use of any one of claims 1-4, wherein administration of the pharmaceutical composition provides relief from one or more symptoms of allergic rhinitis within 15 minutes of administration.

6. Use of mometasone furoate and olopatadine hydrochloride in the manufacture of a fixed-dose pharmaceutical composition for treating allergic rhinitis in a pediatric human subject in need thereof, wherein

(i) the composition is to be nasally administered as one spray per nostril of the pediatric human subject twice daily,

(ii) the composition comprises a hydrocolloid at a concentration of 0.1 % w/w to 3 % w/w,

(iii) each spray comprises about 25 mcg of mometasone furoate and about 665 mcg olopatadine hydrochloride,

(iv) the fixed-dose pharmaceutical composition is a suspension wherein the mometasone furoate is in particulate form with a mean particle size of from 1 to 20 μm, and the olopatadine hydrochloride is in solution form,

(v) the administration provides relief from one or more symptoms of allergic rhinitis faster than nasal administration of 25 mcg mometasone furoate or 665 mcg olopatadine hydrochloride alone, and

(vi) the pediatric human subject is aged 6 to under 12 years.

7. Use of mometasone furoate and olopatadine hydrochloride in the manufacture of a pharmaceutical composition for treating allergic rhinitis in a pediatric human subject, wherein

(a) the composition is prescribed to a pediatric human subject for twice daily nasal administration of one spray per nostril, wherein

(i) the pharmaceutical composition comprises mometasone furoate, olopatadine hydrochloride, and a hydrocolloid at a concentration of 0.1 % w/w to 3 % w/w,

(ii) each spray of the pharmaceutical composition comprises about 25 mcg of mometasone furoate and about 665 mcg of olopatadine hydrochloride,

(iii) the pharmaceutical composition is a suspension wherein the mometasone furoate is in particulate form with a mean particle size of from 1 to 20 μm, and the olopatadine hydrochloride is in solution form, and

(iv) the pediatric human subject is aged 6 to under 12 years,

(b) the prescribing is performed in response to (A) marketing of the pharmaceutical composition as providing (I) faster onset of action for relief of one or more symptoms of allergic rhinitis than nasal administration of mometasone furoate or olopatadine hydrochloride

alone or (II) onset of action for relief of one or more symptoms of allergic rhinitis within 15 minutes of administration, and (B) diagnosis of the subject as suffering from allergic rhinitis; and

(c) the composition is to be nasally administered as one spray per nostril of the pediatric human subject twice daily.

8. The use of claim 7, wherein the symptoms are selected from nasal congestion, rhinorrhea, itching and sneezing.

9. Use of mometasone furoate and olopatadine hydrochloride in the manufacture of a pharmaceutical composition for treating allergic rhinitis in a pediatric human subject, wherein

(i) the composition is to be nasally administered as one spray per nostril of the pediatric human subject twice daily,

(ii) the pharmaceutical composition comprises mometasone furoate, olopatadine hydrochloride, and a hydrocolloid at a concentration of 0.1 % w/w to 3 % w/w, each spray of the pharmaceutical composition comprises about 25 mcg of mometasone furoate and about 665 mcg of olopatadine hydrochloride, and the pharmaceutical composition is a suspension wherein the mometasone furoate is in particulate form with a mean particle size of from 1 to 20 μm, and the olopatadine hydrochloride is in solution form,

(iii) the pharmaceutical composition is to be administered to the pediatric human subject after being prescribed in response to (a) marketing of the pharmaceutical composition as providing (I) faster onset of action for relief of symptoms of allergic rhinitis than nasal administration of mometasone furoate or olopatadine hydrochloride or (II) onset of action for relief of one or more symptoms of allergic rhinitis within 15 minutes of administration, and (b) a diagnosis of the pediatric human subject as suffering from allergic rhinitis, and

(iv) the pediatric human subject is aged 6 to under 12 years.

10. The use of claim 9, wherein the symptoms are selected from nasal congestion, rhinorrhea, itching and sneezing.

11. Use of mometasone furoate and olopatadine hydrochloride in the manufacture

of a pharmaceutical composition for treating allergic rhinitis in a pediatric human subject in need thereof, wherein

(i) the composition is to be nasally administered as one spray per nostril of the pediatric human subject twice daily,

(ii) the composition comprises a hydrocolloid at a concentration of 0.1 % w/w to 3 % w/w,

(iii) the pharmaceutical composition provides an onset of action within 15 minutes for the treatment of allergic rhinitis,

(iv) each spray of the pharmaceutical composition comprises about 25 mcg of mometasone furoate and about 665 mcg of olopatadine hydrochloride,

(v) the pharmaceutical composition is a suspension wherein the mometasone furoate is in particulate form with a mean particle size of from 1 to 20 μm, and the olopatadine hydrochloride is in solution form, and

(vi) the pediatric human subject is aged 6 to under 12 years;

wherein the administration provides improvement in one or more nasal symptom scores: (i) the total nasal symptoms score (TNSS) of the human is reduced by at least 40 % from baseline after 2 weeks treatment, and/or (ii) total ocular symptom score (TOSS) of the human is reduced by at least 30 % from baseline after 2 weeks treatment, and (iii) no significant treatment-related adverse effects are observed in the human after 2 weeks treatment.